Ocugen Gets Wall Street Boost: Oppenheimer Initiates Outperform Coverage with $10 Price Target
Oppenheimer starts coverage on Ocugen with an Outperform rating and $10 price target, highlighting its lead gene therapy OCU400 in Phase 3 for retinitis pigmentosa and big market potential by 2027.
